Palvella Therapeutics, Inc.
PVLA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $26 | $31 |
| % Growth | – | -100% | -17.6% | – |
| Cost of Goods Sold | $0 | $0 | $3 | $2 |
| Gross Profit | $0 | $0 | $23 | $29 |
| % Margin | – | – | 89.3% | 92.5% |
| R&D Expenses | $8 | $9 | $50 | $64 |
| G&A Expenses | $6 | $3 | $0 | $0 |
| SG&A Expenses | $6 | $3 | $16 | $17 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $14 | $12 | $67 | $81 |
| Operating Income | -$14 | -$12 | -$43 | -$52 |
| % Margin | – | – | -167.8% | -165% |
| Other Income/Exp. Net | -$3 | $31 | $10 | $6 |
| Pre-Tax Income | -$17 | $19 | -$33 | -$46 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$17 | $19 | -$33 | -$46 |
| % Margin | – | – | -128.5% | -145.6% |
| EPS | -7.83 | 14.74 | -29.61 | -56.69 |
| % Growth | -153.1% | 149.8% | 47.8% | – |
| EPS Diluted | -7.83 | 14.74 | -29.61 | -56.69 |
| Weighted Avg Shares Out | 2 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 2 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $6 | $1 | $0 |
| Interest Expense | $4 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $3 | $2 |
| EBITDA | -$13 | $19 | -$30 | -$43 |
| % Margin | – | – | -117.7% | -138% |